期刊文献+

薛建国从中医视角运用5型磷酸二脂酶抑制剂体会 被引量:2

XUE Jianguo’s Experience in Application of Phosphodiesterase Type 5 Inhibitors from Perspective of Traditonal Chinese Medicine
下载PDF
导出
摘要 5型磷酸二脂酶抑制剂(PDE5i)是治疗男性勃起功能障碍的一线经典用药,薛建国教授从中医视角分析总结了PDE5i的药性、功效及作用特点,认为PDE5i味辛性平,主入肝经,功能疏肝通络起痿,对肝郁、血瘀型阳痿患者疗效最佳,辨证属于肝肾阴亏、肝阳上亢、气血不足的患者要慎用PDE5i。薛老师还提出了相应的中医配合疗法,为中医临床更好地运用PDE5i提供了借鉴。 Phosphodiesterase type 5 inhibitors(PDE5 i) is the first-line classic drug for the treatment of erectile dysfunction(ED). Professor XUE Jianguo analyzed the pharmacological properties,efficacy and action characteristics of PDE5 i from the perspective of traditional Chinese medicine.He believes that PDE5 i is pungent in taste and plain in nature. It mainly enters the liver meridian and its function is dispersing the liver,removing obstruction in collaterals and erecting impotence. It has the best effect for patients with impotence of liver stagnation or blood stasis syndrome. However,patients with impotence of liver and kidney yin deficiency,liver yang hyperactivity and qi and blood deficiency should used PDE5 i cautiously. The corresponding treatment methods of traditional Chinese medicine were proposed by Mr. XUE,providing experience for better application of PDE5 i in traditional Chinese medicine clinical practice.
作者 张坚 薛建国 ZHANG Jian;XUE Jianguo(The First Clinical Medical College of Nanjing University of Chinese Medicine,Nanjing 210046,China)
出处 《山东中医杂志》 2018年第8期678-680,共3页 Shandong Journal of Traditional Chinese Medicine
关键词 5型磷酸二脂酶抑制剂 西药中用 功效特点 阳痿 Phosphodiesterase type 5 inhibitors useing western medicine from perspective of traditional Chinese medicine action characteristics erectile dysfunction
  • 相关文献

参考文献3

二级参考文献72

  • 1辛钟成.伐地那非的心血管安全性研究[J].中华男科学杂志,2004,10(10):790-793. 被引量:2
  • 2秦国政,骆斌.勃起功能障碍中医体质学规律研究[J].北京中医药大学学报,2005,28(4):74-77. 被引量:32
  • 3唐庆来,高存阁,陈利生,杨波,陈玉海.西地那非致阴茎异常勃起2例报告[J].中国男科学杂志,2006,20(10):54-54. 被引量:2
  • 4Hatzimouratidis K,Amar E,Eardley I,et al. Guidelines on malesexual dysfunction : Erectile dysfunction and premature ejacula-tion. Eur Urol, 2010,57(5) : 804-814.
  • 5Carson CC,Lue TF. Phosphodiesterase type 5 inhibitors for erec-tile dysfunction. BJU Int,2005,96(3) : 257-280.
  • 6Lowe G, Costabile RA. 10-Year analysis of adverse event reportsto the Food and Drug Administration for phosphodiesterase type-5inhibitors. J Sex Med, 2012 , 9(1): 265-270.
  • 7Lange RA, Levine GN. Sexual activity and ischemic heart dis-ease. Curr Cardiol Rep, 2014, 16(2) : 445.
  • 8Giuliano F, Jackson G, Montorsi F,et al. Safety of sildenafil cit-rate :Review of 67 double-blind placebocontrolled trials and thepostmarketing safety database. Int J Clin Pract, 2010,64(2):240-255.
  • 9Ioakeimidis N,Kostis JB. Pharmacologic therapy for erectile dys-function and its interaction with the cardiovascular system. J Car-diovasc Pharmacol Ther, 2014,19( 1 ) : 53-64.
  • 10Rezvanfar MA, Rahimi HR, Abdollahi M. ADMET considera-tions for phosphodiesterase-5 inhibitors. Expert Opin Drug MetabToxicol, 2012,8(10) : 1231-1245.

共引文献61

同被引文献40

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部